VistaGen Therapeutics and AffaMed Therapeutics announced a global phase 3 trial to assess the efficacy, safety and tolerability of a nasal spray that treats adults with social anxiety disorders.
Dubbed the PALISADE Global trial, the companies have submitted necessary data to the FDA under its existing PH94B investigational new drug application for the nasal spray. The trial is expected to begin
/PRNewswire/ AffaMed Therapeutics ("AffaMed"), a global clinical-stage biopharmaceutical company dedicated to developing and commercializing transformative.
VistaGen and AffaMed Complete Key Regulatory Submissions for PALISADE Global Phase 3 Clinical Trial for PH94B - read this article along with other careers information, tips and advice on BioSpace